Cargando…

Monitoring the Effectiveness and Safety of ARNI vs. Angiotensin Receptor Blocker by Frailty Status

Using Medicare data 2015-2017, we conducted 5 sequential 1-to-1 propensity score-matched analyses of ARNI initiators and angiotensin receptor blockers (ARB) initiators, mimicking the accrual of new data every 6 months. Primary effectiveness endpoint was a composite of heart failure hospitalization o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dae, Patorno, Elisabetta, Gopalakrishnan, Chandrasekar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682281/ http://dx.doi.org/10.1093/geroni/igab046.802

Ejemplares similares

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

Trends of ARNI and Other Heart Failure Medication Use in Older Adults
por: Lee, Yu-Chien, et al.
Publicado: (2021)

Monitoring Utilization Trends of Glucose-Lowering Drugs for Type 2 Diabetes in Older Adults by Frailty Status
por: Gopalakrishnan, Chandrasekar, et al.
Publicado: (2021)

UTILIZATION TRENDS OF GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES IN OLDER ADULTS WITH AND WITHOUT DEMENTIA
por: Gopalakrishnan, Chandrasekar, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Prospective Monitoring of Newly Marketed Drugs in Frail Older Adults Using Real-World Databases
por: Kim, Dae, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND SULFONYLUREA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Pawar, Ajinkya, et al.
Publicado: (2019)

FRAILTY AND THE EFFECTIVENESS AND SAFETY OF NEW GLUCOSE-LOWERING DRUGS IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Angiotensin Receptor Blockers Upregulate Angiotensin Type 4 Receptor in Brains of Cognitively Intact Individuals
por: Cosarderelioglu, Caglar, et al.
Publicado: (2021)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine
por: Ohnewein, Bernhard, et al.
Publicado: (2023)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
por: Wang, Xiaobo, et al.
Publicado: (2023)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
por: Dalal, Jamshed, et al.
Publicado: (2023)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
por: Rattanavipanon, Wipharak, et al.
Publicado: (2021)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
por: Bhat, Tahir Saleem, et al.
Publicado: (2022)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data
por: Setoguchi, Soko, et al.
Publicado: (2011)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

My gratitude for Arny's friendship with me
por: Õmura, Satoshi
Publicado: (2021)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
por: Özgür Barış, Veysel, et al.
Publicado: (2022)

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients
por: Corrado, Egle, et al.
Publicado: (2021)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

COMPARATIVE PERFORMANCE OF FOUR CLAIMS-BASED FRAILTY MEASURES IN THE UNITED STATES MEDICARE DATA
por: Kim, Dae H, et al.
Publicado: (2019)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Efficacy and Safety of Angiotensin Receptor Blockers in a Pre-Clinical Model of Arrhythmogenic Cardiomyopathy
por: Landim-Vieira, Maicon, et al.
Publicado: (2022)

ARNi: A Novel Approach to Counteract Cardiovascular Diseases
por: Volpe, Massimo, et al.
Publicado: (2019)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9m03gnpgb8agcotiikgtq25d0a